



**National Jewish
Health**

Advanced Diagnostic
Laboratories

Dear Valued Client:

We are informing you of a manufacturer issue regarding susceptibility testing panels for rapidly growing mycobacteria and other aerobic actinomycetes.

Effective starting Jan. 8, 2024, a backup panel will be used to perform susceptibility testing for rapidly growing mycobacteria (Test code: NTM 6, NTM5; Billing Code: NTM P6, MICSD). The backup panel has fewer drugs (amikacin, ceftazidime, ciprofloxacin, clofazimine, clarithromycin, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, & trimethoprim/sulfamethoxazole) than our routine panel. Note that the panel cost will remain the same.

Susceptibility testing for aerobic actinomycetes (Test Code: NTM4; Billing Code: NTMP4) is delayed for approximately 4 weeks.

We apologize for any inconvenience this may cause. If you have any questions, please contact our Client Service Team at 800-550-6227 or email ClinRefLabs@njhealth.org

Sincerely,

A handwritten signature in blue ink, appearing to read "Steve Groshong".

Steve Groshong, MD, PhD

Medical Director, Advanced Diagnostic Laboratories

National Jewish Health

njlabs.org | 800.550.6227 (toll-free) | 800.652.9556 (fax)

[Unsubscribe](#) from emails from this list.